<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846963</url>
  </required_header>
  <id_info>
    <org_study_id>RC:127</org_study_id>
    <nct_id>NCT00846963</nct_id>
  </id_info>
  <brief_title>Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates</brief_title>
  <acronym>URSONEONAT</acronym>
  <official_title>Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ibrahim Mohamed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ursodiol is effective in the treatment of
      parenteral nutrition associated cholestasis in neonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first randomised controlled study that address the question of the role of
      ursodiol as treatment of cases of PNAC.

      It includes all neonates with stratification of less than and equal to 32 weeks or more than
      32 weeks of gestation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of parenteral nutrition associated cholestasis (in days)</measure>
    <time_frame>at the end of cholestasis (when conjugated bilirubin &lt; 34 mmol/L) average of 4 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak value of biomarkers associated with cholestasis (Gamma-glutamyl transpeptidase, Alkaline phosphatase, conjugated bilirubin)</measure>
    <time_frame>at least once a week, during cholestasis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1- Other hepatic marker (Aspartate transaminase, alanine transaminase, albumin blood level)</measure>
    <time_frame>at least once a week, during cholestasis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length required to minimal enteral feeding (120mL/kg/day) measured in days.</measure>
    <time_frame>From birth to outcome (usually less than 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight gain (in g/kg/day)</measure>
    <time_frame>From birth to resolution of cholestasis (very varuiable but usually less than 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects linked to ursodiol</measure>
    <time_frame>From beginning to the end of the medication (average 4 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Ursodiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned in this arm receive an ursodiol suspension at 20mg/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo suspension that looks like the ursodiol suspension used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodiol</intervention_name>
    <description>Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (&gt;33mmol/L) to the resolution of cholestasis (conjugated bilirubin &lt;34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.
If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given.</description>
    <arm_group_label>Ursodiol</arm_group_label>
    <other_name>Urso</other_name>
    <other_name>ursodeoxycholic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm or in-term newborns hospitalized in neonatal care units at CHU Sainte-Justine
             between October 1st 2008 and October 1st 2011.

          -  Must be receiving parenteral nutrition (either partial or total) at the diagnosis of
             cholestasis.

          -  Parental Consent must be obtained.

        Exclusion Criteria:

          -  Active urinary tract infection

          -  Presence of clinical signs(acholic stool) of or ultrasound evidence of biliary tract
             anomalies.

          -  Positive TORCH infections(Toxoplasmosis, Other infections, Rubella, Cytomegalovirus,
             Herpes simplex virus)

          -  Known short bowel syndrome

          -  Known congenital hypothyroidism

          -  Known genetic disorders associated with cholestasis like galactosemia,
             phenylcytonuria, antitrypsin 1 deficiency... etc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ibrahim Mohamed, MB ChB, DIS P</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josianne Malo, B.Pharm, M.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Al-Hathlol K, Al-Madani A, Al-Saif S, Abulaimoun B, Al-Tawil K, El-Demerdash A. Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med J. 2006 Feb;47(2):147-51.</citation>
    <PMID>16435058</PMID>
  </reference>
  <reference>
    <citation>Arslanoglu S, Moro GE, Tauschel HD, Boehm G. Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. J Pediatr Gastroenterol Nutr. 2008 Feb;46(2):228-31. doi: 10.1097/MPG.0b013e3181560524.</citation>
    <PMID>18223390</PMID>
  </reference>
  <reference>
    <citation>Chen CY, Tsao PN, Chen HL, Chou HC, Hsieh WS, Chang MH. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. J Pediatr. 2004 Sep;145(3):317-21.</citation>
    <PMID>15343182</PMID>
  </reference>
  <reference>
    <citation>Venigalla S, Gourley GR. Neonatal cholestasis. Semin Perinatol. 2004 Oct;28(5):348-55. Review.</citation>
    <PMID>15686266</PMID>
  </reference>
  <reference>
    <citation>McKiernan PJ. Neonatal cholestasis. Semin Neonatol. 2002 Apr;7(2):153-65. Review.</citation>
    <PMID>12208100</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Ibrahim Mohamed</investigator_full_name>
    <investigator_title>Assisstant professor of pediatrics</investigator_title>
  </responsible_party>
  <keyword>parenteral nutrition associated cholestasis in neonates</keyword>
  <keyword>parenteral nutrition induced cholestasis in preterms</keyword>
  <keyword>Bile duct obstruction</keyword>
  <keyword>biliary stasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

